Product Overview
Tirzepatide, also known as Terzepatide, is a dual incretin agonist that activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor.
This dual mechanism makes Tirzepatide a groundbreaking compound in metabolic research, offering insight into the synergistic roles of incretin hormones in regulating appetite, glucose homeostasis, and body weight.
Mechanisms of Action
-
GLP-1 receptor activation: Investigated for appetite suppression, delayed gastric emptying, enhanced insulin secretion, and improved glycemic control.
-
GIP receptor activation: Studied for complementary effects on insulinotropic signaling, nutrient handling, and overall metabolic efficiency.
Key Research Benefits
-
Modeling the effects of dual incretin agonism on energy balance and metabolism.
-
Studying weight loss mechanisms through appetite regulation and caloric intake reduction.
-
Exploring glucose and insulin dynamics in preclinical models of diabetes and obesity.
-
Comparing dual agonist performance against single-pathway incretin analogues.
Disclaimer: All products, including Tirzepatide, are sold for laboratory and research purposes only.
Not for human consumption, medical, or veterinary use





Reviews
There are no reviews yet.